Interferon Patents (Class 424/85.4)
Gamma or immune (Class 424/85.5)
Beta or fibroblast (Class 424/85.6)
Alpha or leukocyte (Class 424/85.7)
  • ANTIVIRAL COMPOUNDS
    Publication number: 20140112885
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 24, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
  • 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION
    Publication number: 20140112887
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?,4?-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2?,4?-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.
    Type: Application
    Filed: October 21, 2013
    Publication date: April 24, 2014
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
  • Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
    Patent number: 8703709
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: April 22, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Anil Gulati
  • COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION
    Publication number: 20140105857
    Abstract: Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 17, 2014
    Applicant: Nexus Pharma, Inc.
    Inventor: Chung Shih
  • MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
    Publication number: 20140105859
    Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Manoj C. DESAI, Allen Yu HONG, Hongtao LIU, Randall W. VIVIAN, Lianhong XU
  • Method of Use and Preparation of HSA Fusion Protein Composition for Skincare
    Publication number: 20140099270
    Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
    Type: Application
    Filed: October 28, 2013
    Publication date: April 10, 2014
    Applicants: FORTUNEROCK, INC. USA, TIANJIN SINOBIOTECH LTD.
    Inventors: Yan Fu, Zailin Yu
  • METHODS OF TREATMENT USING AN AMINOSTEROL COMPOSITION
    Publication number: 20140099281
    Abstract: This invention relates to stable aminosterol phosphate compositions. The aminosterol phosphate compositions permit administration without associated tissue damage and achieve a sustained release effect.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Inventor: Michael Zasloff
  • Camptothecin-Binding Moiety Conjugates
    Publication number: 20140099258
    Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
    Type: Application
    Filed: November 13, 2013
    Publication date: April 10, 2014
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Serengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
  • Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
    Patent number: 8691206
    Abstract: In a process of forming a hydrogel from a mixture comprising hydrogen peroxide (H2O2), horseradish peroxidase (HRP), and a polymer comprising a crosslinkable phenol group, the gelation rate in the solution and the crosslinking density in the hydrogel can be independently adjusted or controlled by selection of the molarity of H2O2 and concentration of HRP in the solution when the molarity of H2O2 is limited to be within a range and the concentration of HRP is limited to be above a threshold. A method for determining the range and threshold is disclosed. The hydrogel may be used to grow cells, in which case, the molarity of H2O2 may be selected to affect the differentiation or growth rate of the cells in the hydrogel. Also, the hydrogel system may be used for sustained delivery of a therapeutic protein, for example in the treatment of liver cancer, fibrosis or hepatitis.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 8, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Motoichi Kurisawa, Li Shan Wang, Joo Eun Chung, Fan Lee, Keming Xu, Hirohisa Yano
  • Compounds and compositions for delivering active agents
    Patent number: 8686154
    Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: April 1, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Donald J. Sarubbi, Eugene N. Barantsevitch
  • PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA
    Publication number: 20140079666
    Abstract: In one aspect, the invention relates to novel, broad-spectrum anti-viral, pyrimidinone compounds, methods of use, compositions and kits useful in treating and/or preventing influenza. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: May 5, 2012
    Publication date: March 20, 2014
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Thomas R. Webb, Vincent A. Boyd
  • Class I Anti-CEA Antibodies and Uses Thereof
    Publication number: 20140079629
    Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
    Type: Application
    Filed: October 29, 2013
    Publication date: March 20, 2014
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
  • THERAPEUTIC ANTI-IGF1R COMBINATIONS
    Publication number: 20140079665
    Abstract: The present invention provides, in part, compositions including an anti-IGF1R antibody or antigen-binding fragment thereof and any one or more of cisplatin, pemetrexed, gemcitabine and/or irinotecan; optionally including or excluding a further chemotherapeutic agent, as well as methods of treating diseases, such as cancer, using such compositions.
    Type: Application
    Filed: May 15, 2012
    Publication date: March 20, 2014
    Inventors: Liliane Goetsch, Karl Hsu
  • TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20140079667
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 20, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Compositions and methods for inhibiting entry of a hepatic virus
    Patent number: 8673288
    Abstract: The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: March 18, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Susan L. Uprichard, Bruno Sainz, Jr.
  • METHOD FOR PREPARING MICROPARTICLES WITH REDUCED INITIAL BURST AND MICROPARTICLES PREPARED THEREBY
    Publication number: 20140072531
    Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 13, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES
    Publication number: 20140072532
    Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.
    Type: Application
    Filed: October 11, 2013
    Publication date: March 13, 2014
    Applicant: MICRODOSE THERAPEUTX, INC.
    Inventors: Theodore J. Nitz, Janet A. Gaboury, Christopher J. Burns, Sylvie Laguerre, Daniel C. Pevear, Thomas A. Lessen, David J. Rys
  • 2'-Branched Nucleosides for Treatment of Viral Infections
    Publication number: 20140065101
    Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Application
    Filed: August 27, 2013
    Publication date: March 6, 2014
    Applicant: Novartis AG
    Inventor: Fumiaki Yokokawa
  • NOVEL INHIBITORS
    Publication number: 20140065095
    Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Application
    Filed: June 5, 2013
    Publication date: March 6, 2014
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
    Patent number: 8664273
    Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: March 4, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Lindsay McNair, John McHutchison
  • Treating Hepatitis C Virus Infection
    Publication number: 20140056846
    Abstract: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HCV release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.
    Type: Application
    Filed: February 12, 2013
    Publication date: February 27, 2014
    Inventors: Jin Ye, Fang Sun, Hua Huang, Michael J. Gale
  • HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20140050699
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 20, 2014
    Applicant: CALITHERA BIOSCIENCES INC.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • Hepatitis C Virus Inhibitors
    Publication number: 20140050695
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: September 18, 2013
    Publication date: February 20, 2014
    Inventors: Makonen Belema, Van N. Nguyen
  • RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF
    Publication number: 20140050698
    Abstract: This invention provides a method for treating tumors in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the interferon has the amino acid sequence of SEQ ID NO:2 and is encoded by the nucleotide sequence SEQ ID NO:1, wherein the tumors are selected from the group consisting of skin cancer, basal cell carcinoma, liver cancer, thyroid cancer, rhinopharyngeal cancer, solid carcinoma, prostate cancer, esophageal cancer, pancreatic cancer, superficial bladder cancer, hemangioma, epidermoid carcinoma, cervical cancer, glioma, leucocythemia, acute leucocythemia, chronic leucocythemia, lymphadenoma, and polycythemia vera.
    Type: Application
    Filed: September 5, 2013
    Publication date: February 20, 2014
    Applicant: Superlab Far East Limited
    Inventor: Guangwen WEI
  • ANALYSIS OF HCV GENOTYPES
    Publication number: 20140050697
    Abstract: A method for predicting response of a patient infected with HCV-1a to interferon treatment.
    Type: Application
    Filed: June 6, 2013
    Publication date: February 20, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Douglas John Bartels, Ann Dak-Yee Kwong, Tara Lynn Kieffer
  • Anti-Pancreatic Cancer Antibodies
    Publication number: 20140037543
    Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Lea and Le(y) antibodies that bind to the Lewis antigens.
    Type: Application
    Filed: June 6, 2013
    Publication date: February 6, 2014
    Applicant: IMMUNOMEDICS, INC.
    Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang, David V. Gold
  • METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA
    Publication number: 20140037581
    Abstract: The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases.
    Type: Application
    Filed: July 26, 2013
    Publication date: February 6, 2014
    Applicants: The United States of America, as Represented by the Secretary, Department of Health and Human Serv, University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Patrick S. Moore, Yuan Chang, Huichen Feng, Christopher Brian Buck, Diana V. Pastrana
  • Hepatitis C virus inhibitors
    Patent number: 8642025
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: February 4, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
  • INHIBITORS OF FLAVIVIRIDAE VIRUSES
    Publication number: 20140030223
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: September 25, 2013
    Publication date: January 30, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Eda Canales, Lee S. Chong, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Scott E. Lazerwith, Willard Lew, Qi Liu, Michael Martzman, Philip Anthony Morganelli, William J. Watkins, Hong Ye
  • Treatment And Screening
    Publication number: 20140030218
    Abstract: A method of treating a patient having an autoimmune disease or a Th1 polarising infection or a condition associated with inflammation other than asthma or allergy, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of Interferon Regulatory Factor 5 (IRF5).
    Type: Application
    Filed: January 5, 2012
    Publication date: January 30, 2014
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Irina Alexandrovna Udalova, Thomas Krausgruber, Marc Feldmann, David Saliba, Hayley Eames
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES REPLICATION
    Publication number: 20140030224
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 30, 2014
    Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • TREATMENT OF SKIN DISEASE
    Publication number: 20140030314
    Abstract: The present invention is drawn to compositions, systems, and methods of treating skin disease. In one example, the composition includes a peroxygen, a transition metal or alloy thereof, and optionally, an alcohol and/or a drug. The composition can be packaged as part of a two-part system.
    Type: Application
    Filed: January 14, 2013
    Publication date: January 30, 2014
    Inventors: Brian G. Larson, David Larson
  • MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
    Publication number: 20140030221
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: June 7, 2013
    Publication date: January 30, 2014
    Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennec, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar karki, Adam James Schrier, Petr Jansa, Richard Mackman
  • RECOMBINANT FUSION INTERFERON FOR ANIMALS
    Publication number: 20140030222
    Abstract: The present invention relates to a recombinant fusion interferon for animals, a pharmaceutical composition thereof, and the use of the recombinant fusion interferon. The recombinant fusion interferon is represented by formula (I) or formula (II), (Porcine interferon)-(Linker)n-(Porcine immunoglobulin Fc fragment) ??(I) (Porcine immunoglobulin Fc fragment)-(Linker)n-(Porcine Interferon) ??(II) wherein n is 0 or a positive integer between 1 to 10, the recombinant fusion IFN specifically binds an antibody that specifically binds porcine interferon and an antibody that specifically binds porcine immunoglobulin Fc fragment.
    Type: Application
    Filed: July 17, 2013
    Publication date: January 30, 2014
    Applicant: SBC Virbac Biotech Co., Ltd.
    Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
  • RECOMBINANT FUSION INTERFERON FOR ANIMALS
    Publication number: 20140030220
    Abstract: A recombinant fusion interferon for animals. The recombinant fusion interferon comprises an animal interferon and a Fc region of an animal immunoglobulin G (IgG). The animal interferon and the Fc region of the animal immunoglobulin G can be further joined by a linker. A polynucleotide that encodes the recombinant fusion interferon for animals, a method for producing the recombinant fusion interferon, and the use of the recombinant fusion interferon.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 30, 2014
    Applicant: SBC Virbac Biotech Co., Ltd.
    Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
  • MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
    Publication number: 20140023616
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 23, 2014
    Applicants: Selcia Limited, Gilead Sciences, Inc.
    Inventors: Todd Appleby, Hans G. Fliri, Andrew J. Kaets, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Jonathan Sanvoisin, Victoria A. Steadman, Gregory M. Watt
  • MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
    Publication number: 20140017199
    Abstract: The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 16, 2014
    Inventors: Manoj C. Desai, Allen Yu Hong, Hon Chung Hui, Hongtao Liu, Randall W. Vivian, Lianhong Xu
  • Hepatitis C Virus Inhibitors
    Publication number: 20140017195
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: September 9, 2013
    Publication date: January 16, 2014
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavole, Omar D. Lopez, Alain Martel, Nicolas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
  • Anti-CD19 Antibodies
    Publication number: 20140017197
    Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.
    Type: Application
    Filed: June 17, 2013
    Publication date: January 16, 2014
    Applicant: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
  • INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20140017198
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 16, 2014
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil Kumar Karki, Ashley Anne Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-Jung Pyun, Michael Sangi, Adam James Schrier, Dustin Siegel, James G. Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • ANTIVIRAL COMPOUNDS
    Publication number: 20140010783
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 9, 2014
    Inventors: Joseph A. Bilotta, Zhi Chen, Elbert Chin, Qingjie Ding, Shawn D. Erickson, Stephen D. Gabriel, Klaus G. Klumpp, Han Ma, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert
  • Antiviral drugs for treatment of arenavirus infection
    Patent number: 8623347
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family is disclosed.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 7, 2014
    Assignee: Siga Technologies, Inc.
    Inventors: Dongcheng Dai, Dennis E. Hruby, Tove C. Bolken, Sean M. Amberg, Travis K. Warren
  • ANGIOPOIETIN DERIVED PEPTIDES
    Publication number: 20140004175
    Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
    Type: Application
    Filed: June 18, 2013
    Publication date: January 2, 2014
    Applicant: Compugen Ltd.
    Inventors: Yossef KLIGER, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
  • Immunoconjugates with an Intracellularly-Cleavable Linkage
    Publication number: 20140004078
    Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.
    Type: Application
    Filed: June 19, 2013
    Publication date: January 2, 2014
    Applicant: IMMUNOMEDICS, INC.
    Inventor: Serengulam V. Govindan
  • MULTI-FUNCTIONAL POLYMERIC MATERIALS AND THEIR USES
    Publication number: 20130344027
    Abstract: Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 26, 2013
    Applicant: University of Tennessee Research Foundation
    Inventors: Tao Lu Lowe, Young Shin Kim, Xiao Huang
  • SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20130344031
    Abstract: Compounds represented by formula (Ia) or (Ib) and wherein R and R1 are as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 26, 2013
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Maria Gabriella Brasca, Raffaella Amici, Daniele Fancelli, Marcella Nesi, Paolo Orsini, Fabrizio Orzi, Patrick Roussel, Anna Vulpetti, Paolo Pevarello
  • MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
    Publication number: 20130344029
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennac, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar Karki, Adam James Schrier, Petr Jansa, Richard Mackman
  • 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
    Publication number: 20130344028
    Abstract: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: October 11, 2012
    Publication date: December 26, 2013
    Inventors: Thomas BUTLER, Aesop CHO, Choung U. KIM, Jay P. PARRISH, Oliver L. SAUNDERS, Lijun ZHANG
  • MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
    Publication number: 20130344030
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Inventors: Victoria Alexandra Steadman, Karine G. Poullennec, Linos Lazarides, Caroline Aciro, David Kenneth Dean, Andrew John Keats, Dustin Scott Siegel, Adam James Schrier, Richard Mackman, Petr Jansa
  • Peptidomimetic sulfamide compounds and antiviral uses thereof
    Patent number: 8613914
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic